Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo
about
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivoSynergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells.Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
P2860
Q35741591-02B5429F-83D7-4BB1-BFA8-631D973CFB5BQ35828564-4C23F653-29EE-484A-BD4C-E792F143283DQ37190466-2F9B9F71-CF0A-4404-A733-FB8DEA060F18Q37295668-3804EE5A-5DC0-41E5-8FAF-905F9E021C1DQ37413127-CD02E0C0-F83C-4EA0-968B-35B9E6A9778EQ37612692-03E638F8-3FC8-461B-9C5E-399EDCF05F4AQ37613829-67CB7DCF-4FD5-4683-90D9-F1F1CB3C767CQ38635603-20BEFBD9-0AFC-4AD8-86F4-62222544FFAEQ38902765-A3773869-F34C-4F93-BDF8-923E63AAAD71Q38984146-41043C9A-2CE3-4C39-8174-78C1C1EF27F2Q43203316-C2A3E3CF-F7DC-45EA-800C-B90119964059Q48595586-382DBEA8-0A23-4BE8-A250-B705F774F939Q49334697-E9646DA3-3DC7-4AC8-8D94-5E5C3E1F8466Q59132751-B6E18491-A3EA-4E7F-9D93-4323256671C5
P2860
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@ast
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@en
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@nl
type
label
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@ast
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@en
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@nl
prefLabel
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@ast
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@en
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@nl
P2093
P2860
P1476
Synergistic interaction betwee ...... cer cells in vitro and in vivo
@en
P2093
An-Chi Tsai
Ching-Shih Chen
Chun-Han Chen
Jing-Chi Wang
Jing-Ping Liou
Mei-Chuan Chen
Shiow-Lin Pan
P2860
P304
P356
10.1158/1078-0432.CCR-12-3909
P407
P577
2014-02-11T00:00:00Z